0001415889-24-015552.txt : 20240605 0001415889-24-015552.hdr.sgml : 20240605 20240605161149 ACCESSION NUMBER: 0001415889-24-015552 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240603 FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES CENTRAL INDEX KEY: 0001221590 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39264 FILM NUMBER: 241022125 MAIL ADDRESS: STREET 1: 925 PAGE MILL ROAD CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Keros Therapeutics, Inc. CENTRAL INDEX KEY: 0001664710 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 811173868 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1050 WALTHAM STREET, SUITE 302 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-314-6297 MAIL ADDRESS: STREET 1: 1050 WALTHAM STREET, SUITE 302 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 form4-06052024_080645.xml X0508 4 2024-06-03 0001664710 Keros Therapeutics, Inc. KROS 0001221590 BIENAIME JEAN JACQUES C/O KEROS THERAPEUTICS, INC. 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 true false false false 0 Stock Option (right to buy) 48.67 2024-06-03 4 A 0 17600 0 A 2034-06-02 Common Stock 17600 17600 D One-twelfth (1/12th) of the shares subject to the option shall vest in equal quarterly installments commencing on September 3, 2024, subject to the Reporting Person continuing to provide service through each such date. /s/ Keith Regnante, Attorney-in-Fact 2024-06-05